ВАРІАНТ ГЕНА TP53 (rs 1625895, 13494G>A) ПОВ’ЯЗАНИЙ ІЗ ЛОКАЛІЗАЦІЄЮ НОВОУТВОРЕННЯ У ХВОРИХ НА ЛЕЙОМІОМУ МАТКИ

• Date: 2023
• Main Authors: Kornatska, A.G., Flaksemberg, М.А., Chubei, G.V., Trokhymovych, О.V., Rossokha, Z.I., Fishchuk, L.Ye., Medvedieva, N.L., Vershyhora, V.O., Gorovenko, N.G.
• Format: Article
• Language: English
• Published: PH Akademperiodyka 2023
• Subjects: лейоміома матки; ризик розвитку; варіанти гена TP53; локалізація новоутворення. лейоміома матки; локалізація новоутворення.
• Online Access: https://exp-oncology.com.ua/index.php/Exp/article/view/2021-2-12
• Journal Title: Experimental Oncology

Summary. Background: Uterine leiomyoma (UL) is the most common benign neoplasm of the uterus. It is still unknown surely what exactly initiates transformation of the uterine myometrial cells into UL. Aim: To study the effect of the TP53 gene variants on the risk of development and clinical features of UL. Materials and Methods: Case-control study was performed using molecular genetic analyses of variants rs1042522 (119 G>C) and rs1625895 (13494G>A) of TP53 gene in patients with UL and comparison group of healthy women. Results: Investigated TP53 gene variants were not associated with the risk of UL development. The patients with the 13494GG genotype (rs1625895) had significantly more often subserous UL (р < 0.05). In patients with heterozygous variant of TP53 — 13494GA genotype (rs1625895) intramural UL was observed (р < 0.05). Conclusions: The rs1625895 (13494G>A) variant of TP53 gene was associated with UL localization. The identified dependence of the UL localization on the TP53 gene variant could be useful for personalized approach to treatment.